HUP0004070A3 - Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione - Google Patents
Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dioneInfo
- Publication number
- HUP0004070A3 HUP0004070A3 HU0004070A HUP0004070A HUP0004070A3 HU P0004070 A3 HUP0004070 A3 HU P0004070A3 HU 0004070 A HU0004070 A HU 0004070A HU P0004070 A HUP0004070 A HU P0004070A HU P0004070 A3 HUP0004070 A3 HU P0004070A3
- Authority
- HU
- Hungary
- Prior art keywords
- thiazolidine
- dione
- pyridyl
- ethoxy
- benzyl
- Prior art date
Links
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9711683.4A GB9711683D0 (en) | 1997-06-05 | 1997-06-05 | Composition |
| GBGB9712851.6A GB9712851D0 (en) | 1997-06-18 | 1997-06-18 | Composition |
| PCT/EP1998/003478 WO1998055122A1 (en) | 1997-06-05 | 1998-06-02 | Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0004070A2 HUP0004070A2 (hu) | 2002-02-28 |
| HUP0004070A3 true HUP0004070A3 (en) | 2002-03-28 |
Family
ID=26311662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0004070A HUP0004070A3 (en) | 1997-06-05 | 1998-06-02 | Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0998284A1 (hu) |
| JP (1) | JP2001521553A (hu) |
| KR (1) | KR20010013410A (hu) |
| CN (3) | CN1112926C (hu) |
| AP (1) | AP1214A (hu) |
| AR (2) | AR008198A1 (hu) |
| AU (1) | AU8215098A (hu) |
| BG (1) | BG104048A (hu) |
| BR (1) | BR9810405A (hu) |
| CA (2) | CA2333352A1 (hu) |
| CO (1) | CO4940400A1 (hu) |
| DZ (1) | DZ2510A1 (hu) |
| EA (1) | EA002384B1 (hu) |
| GB (1) | GB9711683D0 (hu) |
| HU (1) | HUP0004070A3 (hu) |
| ID (1) | ID24264A (hu) |
| IL (1) | IL133074A0 (hu) |
| MX (1) | MXPA99011322A (hu) |
| NO (2) | NO995938L (hu) |
| NZ (2) | NZ523725A (hu) |
| OA (1) | OA11306A (hu) |
| PE (1) | PE78899A1 (hu) |
| PL (1) | PL337201A1 (hu) |
| SK (1) | SK164899A3 (hu) |
| TR (2) | TR199902963T2 (hu) |
| TW (1) | TW570797B (hu) |
| UY (1) | UY25032A1 (hu) |
| WO (1) | WO1998055122A1 (hu) |
| ZA (2) | ZA9811572B (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200103061T2 (tr) | 1999-04-23 | 2002-05-21 | Smithkline Beecham P.L.C. | Yeni farmasötik madde. |
| US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| EP1173435B1 (en) * | 1999-04-23 | 2003-07-30 | SmithKline Beecham plc | Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| GB0021978D0 (en) | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
| WO2003050112A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Toluenesulfonate hydrates of a thiazolidinedione derivative |
| GB0129876D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0129871D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0130509D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| EP2270007A1 (en) * | 2006-05-09 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE186724T1 (de) * | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| WO1995021608A1 (en) * | 1994-02-10 | 1995-08-17 | Smithkline Beecham Plc | Use of insulin sensitisers for treating renal diseases |
| SK16498A3 (en) * | 1995-08-10 | 1999-03-12 | Warner Lambert Co | A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus |
| WO1997018811A1 (en) * | 1995-11-17 | 1997-05-29 | Warner-Lambert Company | A method of treating myotonic dystrophy |
| NZ314406A (en) * | 1996-03-18 | 2000-12-22 | Sankyo Co | Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles |
| WO1998002159A1 (en) * | 1996-07-12 | 1998-01-22 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
-
1997
- 1997-06-05 GB GBGB9711683.4A patent/GB9711683D0/en active Pending
-
1998
- 1998-06-02 EA EA199901116A patent/EA002384B1/ru not_active IP Right Cessation
- 1998-06-02 TR TR1999/02963T patent/TR199902963T2/xx unknown
- 1998-06-02 ID IDW991520A patent/ID24264A/id unknown
- 1998-06-02 SK SK1648-99A patent/SK164899A3/sk unknown
- 1998-06-02 AU AU82150/98A patent/AU8215098A/en not_active Abandoned
- 1998-06-02 PL PL98337201A patent/PL337201A1/xx unknown
- 1998-06-02 CA CA002333352A patent/CA2333352A1/en not_active Abandoned
- 1998-06-02 IL IL13307498A patent/IL133074A0/xx unknown
- 1998-06-02 WO PCT/EP1998/003478 patent/WO1998055122A1/en not_active Application Discontinuation
- 1998-06-02 KR KR19997011411A patent/KR20010013410A/ko not_active Application Discontinuation
- 1998-06-02 AP APAP/P/1999/001696A patent/AP1214A/en active
- 1998-06-02 NZ NZ523725A patent/NZ523725A/en unknown
- 1998-06-02 CN CN98805686A patent/CN1112926C/zh not_active Expired - Lifetime
- 1998-06-02 BR BR9810405-5A patent/BR9810405A/pt not_active IP Right Cessation
- 1998-06-02 EP EP98932144A patent/EP0998284A1/en not_active Withdrawn
- 1998-06-02 HU HU0004070A patent/HUP0004070A3/hu unknown
- 1998-06-02 CA CA002292629A patent/CA2292629C/en not_active Expired - Fee Related
- 1998-06-02 JP JP50158799A patent/JP2001521553A/ja not_active Ceased
- 1998-06-02 CN CNA2003101199090A patent/CN1526391A/zh active Pending
- 1998-06-02 MX MXPA99011322A patent/MXPA99011322A/es unknown
- 1998-06-02 TR TR2000/02790T patent/TR200002790T2/xx unknown
- 1998-06-03 DZ DZ980120A patent/DZ2510A1/xx active
- 1998-06-04 UY UY25032A patent/UY25032A1/es not_active IP Right Cessation
- 1998-06-04 CO CO98031614A patent/CO4940400A1/es unknown
- 1998-06-04 ZA ZA9811572A patent/ZA9811572B/xx unknown
- 1998-06-04 AR ARP980102649A patent/AR008198A1/es not_active Application Discontinuation
- 1998-06-04 ZA ZA9804826A patent/ZA984826B/xx unknown
- 1998-06-04 AR ARP980102650A patent/AR015120A1/es not_active Application Discontinuation
- 1998-06-05 PE PE1998000466A patent/PE78899A1/es not_active Application Discontinuation
- 1998-10-23 TW TW087117536A patent/TW570797B/zh not_active IP Right Cessation
-
1999
- 1999-12-02 OA OA9900267A patent/OA11306A/en unknown
- 1999-12-03 NO NO995938A patent/NO995938L/no not_active Application Discontinuation
- 1999-12-27 BG BG104048A patent/BG104048A/bg unknown
-
2001
- 2001-09-03 NZ NZ513922A patent/NZ513922A/xx unknown
-
2002
- 2002-11-05 CN CN02149972A patent/CN1430959A/zh active Pending
-
2004
- 2004-02-20 NO NO20040738A patent/NO20040738L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL151425A0 (en) | Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino)ethoxy]benzyl] thiazolidine-2,4-dione | |
| AU4600493A (en) | Monohydrate of 5-(2-(4-(1,2 benzisothiazol-3-yl) -1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride | |
| IL146111A0 (en) | 5-[4-[2-(n-methyl-n-(2-pyridyl) amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt | |
| PL341146A1 (en) | Maleic 5-[4-[2-(n-methyl-n-(2-pyridil)amino)ethoxy]benzyl]thiazolydin-2,4-dione salt hydrate as a pharmacological agent | |
| IL133074A0 (en) | Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione | |
| IL155036A0 (en) | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same | |
| AP2000001830A0 (en) | Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt | |
| NO2009002I1 (no) | 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid | |
| AU2002343036A1 (en) | 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical compositions comprising the same | |
| HUP0300938A3 (en) | The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
| IL160144A0 (en) | Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2, 4-dione | |
| IL188116A0 (en) | Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione | |
| HU9802874D0 (en) | Process for making 2-(methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole using methyldithiocarbazinate | |
| GB0021784D0 (en) | Novel pharmaceutical | |
| AU6255001A (en) | 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical | |
| AU2002352481A1 (en) | 5- (4- (2- (n-methyl-n- (2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione nephtalenesulfonate salt and use against diabetes mellitus | |
| AU1272701A (en) | Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4- dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist | |
| IL166189A (en) | 5-{4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl}-5-{1-[2, 4-dioxothiazolidine-5-yl]-1-[4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) phenyl] methyl}-2,4-thiazolidinedione and tautomeric form, salt or solvate thereof | |
| AU2002222305A1 (en) | 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt | |
| SI1265893T1 (sl) | Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona |